Neuroprotective Role of Ketamine in Reducing Neuroinflammation and Enhancing Neuroplasticity Against a Cortisol-Induced In Vitro Stress Model.
Lucas Santos, Fernanda Dos Santos Petry, Carolina Saibro-Girardi, Júlia Hansen, Danielle Martins, Nicole Fröhlich, Luana Possa, Luiz Filipe Bastos Mendes, Hémelin Resende Farias, Alberto Martins Silva, Izabbela Giacon Deitos, Reykla Ramon Bittencourt, Jade de Oliveira, Daniel Pens Gelain, Roberto F Almeida, José Cláudio Fonseca Moreira
Molecular neurobiology June 5, 2025 DOI: 10.1007/s12035-025-05114-x via PubMed
Summary
AI-generated from the abstractCortisol, a stress hormone, damages neural-like cells by reducing their survival, increasing inflammatory gene activity (NF-κB and NLRP3), boosting production of reactive oxygen species, and impairing neuroplasticity—lowering BDNF expression and reducing neurite growth and neural connections. Ketamine prevented, attenuated, and reversed these cortisol-induced effects: it reduced inflammation and reactive species, increased BDNF expression, and promoted neurite growth and connectivity. Using an in vitro model, the work demonstrates that ketamine's mechanism of action includes reducing neuroinflammation and enhancing neuroplasticity, beyond its known NMDA receptor antagonism.
Study at a glance
| Characteristics | In vitro study Peer reviewed |
|---|---|
| Population | Neural-like cells |
| Intervention | Ketamine |
| Topics | Ketamine |
| Keywords | Bdnf Cortisol Nf-κb Nlrp3 |
| Citations | 4 |
| Key finding | Ketamine prevents, attenuates, and reverses cortisol-induced inflammation and impaired neuroplasticity in neural-like cells, indicating its mechanism extends beyond NMDA receptor antagonism. |
Abstract
Stress is widely recognized as a major environmental factor contributing to the development of mood disorders. In patients with Major Depressive Disorder (MDD) and suicidal behavior, significant hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis is observed, characterized by excessive cortisol release, which in turn stimulates the production of pro-inflammatory mediators. Inflammation affects approximately one in four patients with MDD and is associated with treatment resistance. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist used in patients with severe and treatment-resistant MDD, has emerged as a relevant target for investigation. However, the precise mechanism of action of this drug remains unclear. In this study, we investigated the neuroprotective effects of ketamine in response to cortisol using in vitro stress models with neural-like cells. We observed that cortisol reduced cell viability, increased the expression of inflammatory genes such as NF-κB and NLRP3, and enhanced the production of reactive oxygen species. Additionally, cortisol impaired neuroplasticity by reducing BDNF expression and diminishing the number and length of primary and secondary neurites, as well as overall neural connectivity. Ketamine was found to prevent, attenuate, and even reverse cortisol-induced expression of inflammatory genes and reactive species production. Moreover, ketamine significantly increased BDNF expression and promoted the growth and elongation of primary neurites and neural connections. For the first time, using an in vitro model of cortisol-induced stress in neural-like cells, we demonstrated that ketamine's mechanism of action extends beyond NMDA receptor antagonism to include the reduction of neuroinflammation and the enhancement of neuroplasticity.